Halozyme Therapeutics (HALO) Stock Forecast & Price Target

Halozyme Therapeutics is viewed positively because its royalty engine is accelerating across multiple launches, with 2Q26 royalty revenue of about $307.7M and total revenue of $481.0M both beating estimates, while management raised 2026 guidance for revenue, royalties, adjusted EBITDA, and non-GAAP EPS. The outlook is further strengthened by rapid adoption of subcutaneous products, including 44k patients on subcutaneous OCREVUS, 15% conversion for OPDIVO, 54% conversion for PHESGO, and 62% Y/Y growth in RYBREVANT, which supports durable ENHANZE demand and expanding royalty streams. Fundamentally, the company has a deep partnership pipeline with four collaborations in 2Q26 plus a fifth in July, 9 ENHANZE products in development, and a disciplined balance sheet path toward 1.1x net leverage by YE2026, while ongoing deal momentum and new modality expansion reinforce the durability of its platform.

Halozyme Therapeutics is weighed down by substantial technology, clinical, regulatory, commercial, and balance sheet risks that can undermine both development and valuation. Although PH20 has shown no known safety issues to date, any future safety signal could delay or halt commercialization, while partners’ candidates may fail in clinical trials or face FDA and other regulatory rejections requiring additional studies. Commercially, even successful products must compete with existing and emerging therapies, and high development costs raise the risk of returning to capital markets, while the 48,700 impairment of intangible asset highlights weak asset quality.